Skip to content

MDMA: all studies

Page 13 of 345: studies 121 to 130 of 3,446, newest first. Back to the MDMA overview

Research

Psychoactive Synthetic Adulterants in Tablets Sold as MDMA after the COVID-19 Pandemic: Implications for Central Effects.

Current Neuropharmacology January 9, 2026 Maria Antonietta De Luca, Cristina Miliano, Amanda Roxburgh et al. 1 citation

Preclinical and clinical studies reported that 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') can cause adverse effects in the central nervous system (CNS). Recently, preclinical studies have demonstrated that certain psychoactive substances may exacerbate the noxious central effects of MDMA when co-administered, including substances that are contained as adulterants in tablets sold as...

The case for an integrative model: Hypotheses and rationale for integrative MDMA-Assisted Psychotherapy (IMAP)

Psychedelics January 8, 2026 Rachel Yehuda, Amy Lehrner, Miryam Sperka et al. 2 citations

The original MAPS manual for MDMA-assisted therapy (MDMA-AT) opened a therapeutic frontier for PTSD. However, it drew critique for concepts—such as “inner healing intelligence” – that originated in transpersonal traditions rather than academic or empirically grounded clinical models. While many patients found the therapies helpful, these constructs were difficult to interpret and standardize....

DOI: 10.1016/j.psyche.2026.100008 (opens in new tab) Mindfulness Mainstream Transpersonal Foundation evidence +17

Severe 3,4-Methylenedioxymethamphetamine (MDMA)-Associated Rhabdomyolysis in Crohn's Disease: Direct Toxicity and Inflammatory Susceptibility in the Absence of Hyperthermia.

Cureus 2026 Sebastian Hernandez Mejia, Aishwarya Ashwinee, Ranwa Aldaker

Rhabdomyolysis is a recognized complication of 3,4-methylenedioxymethamphetamine (MDMA), usually driven by severe hyperthermia and agitation. We describe a previously healthy 45-year-old man who developed profound rhabdomyolysis (creatine kinase (CK) 160,000 U/L) and intrinsic acute kidney injury requiring hemodialysis after ingesting 1.5 g of "Molly" (pure MDMA), despite remaining afebrile...

DOI: 10.7759/cureus.101526 (opens in new tab) Full text (opens in new tab) 4-Methylenedioxymethamphetamine MDMA Acute kidney injury Chron's disease Inflammatory bowel disease +4

New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report

Case Reports in Psychiatry 2026 Ridhi J. Vyas, Ryan Hood, Jeremy Hsiang et al.

3,4‐Methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy (MDMA‐AP) has shown promise in treating post‐traumatic stress disorder (PTSD), particularly in treatment‐resistant cases. However, little is known about its potential to precipitate adverse psychiatric outcomes. We present the case of a 31‐year‐old woman with nondistressing childhood compulsions, chronic PTSD, and complex medical...

Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants.

Neuropsychopharmacology 2026 Isabelle Straumann, Patrick Vizeli, Isidora Avedisian et al. 5 citations

3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally, as a research tool, and in MDMA-assisted therapy in patients with posttraumatic stress disorder. 3,4-Methylenedioxyamphetamine (MDA) is a psychoactive metabolite of MDMA. Acute effects of MDMA and MDA have never been directly compared in humans. Lysine-conjugated amphetamines slowly release active amphetamine once absorbed,...

Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study.

Frontiers in Neuroscience 2026 Jenna E Kachmarik, Jennifer M Loftis, Christopher S. Stauffer

Posttraumatic stress disorder (PTSD) is associated with elevated inflammation and risk for chronic illness, yet few studies have examined inflammatory biomarker outcomes of PTSD interventions. Rapid PTSD symptom reduction has been observed following 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy, which leverages MDMA as a prosocial adjunct to psychotherapy. No studies have evaluated...

The entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") disrupts helping behaviour while reinforcing electrophysiological indicators of potentially associated synaptic plasticity in male Sprague-Dawley rats.

Frontiers in Pharmacology 2026 Patricio Sáez-briones, Amanda Silva-Rodríguez, Michelle Morales-Vidal et al.

In humans, empathy is expressed through various prosocial behaviours between individuals that may be enhanced after intake of the synthetic entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") as the behavioural expression of the so-called entactogenic syndrome. Rodents may also exhibit empathy-like behaviours, such as social interaction and helping behaviour. In this regard, while...

DOI: 10.3389/fphar.2026.1779772 (opens in new tab) Full text (opens in new tab) Serotonin 3,4-methylenedioxymethamphetamine Helping behaviour Oxytocin

Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder

Open Science Framework 2026 Christina Chwyl, M. Kati Lear, Sunjeev K. Kamboj et al. preprint

Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorder (SAD). One proposed mechanism of MDMA-assisted therapy (MDMA-AT) for SAD is the cultivation of self-compassion. Across five aims, we will characterize self-compassion experiences during MDMA-AT and evaluate its role as a potential mechanism of...

Possible Effects of MDMA on Vehicle Driving Competencies

Transportation research procedia 2026 Samuel Hubočan, Matúš Madleňák

Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be assumed that vehicle driving competencies represent one of these factors. A vehicle driver should be vigilant, decisive and capable of practical use of traffic rules implied by the legal system. Addictive substances can disrupt driver’s capabilities...

DOI: 10.1016/j.trpro.2025.12.042 (opens in new tab) MDMA Addiction Poison control Orientation vector space +3

Appearance of necrotizing sialometaplasia temporarily associated with MDMA consumption

Journal of Clinical and Experimental Dentistry 2026 E. Plaza-Matos, J. López-vicente, N. Larrea-Rodríguez et al. 1 citation

We reported the case of a 24-year-old woman presented with necrotizing sialometaplasia associated temporally with 3,4-methylenedioxymethamphetamine (MDMA) use.The patient reported having consumed MDMA powder licked onto the oral mucosa days before the appearance of the lesions.Symptomatic treatment of the presenting lesions was carried out, with a follow-up that demonstrated complete healing of...

DOI: 10.4317/jced.63836 (opens in new tab) MDMA Ecstasy Consumption sociology Mouth mucosa +2